Lysosomal acid lipase deficiency - An under-recognized cause of dyslipidaemia and liver dysfunction

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 21-30

  Reiner, Željko ^a   Guardamagna, Ornella ^b   Nair, Devaki ^c   Soran, Handrean ^d   Hovingh, Kees ^e   Bertolini, Stefano ^f   Jones, Simon ^d   Ćorić, Marijana ^a   Calandra, Sebastiano ^g   Hamilton, John ^h   Eagleton, Terence ⁱ   Ros, Emilio ^j,k  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF TURIN   (Italy)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

ⁱ Synageva BioPharma Corp   (United States)

^j HOSPITAL CLÍNIC   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Cholesteryl ester storage disease; Dyslipidaemia; Hepatomegaly; Lysosomal acid lipase deficiency; Wolman disease

Indexed keywords

ACID LIPASE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT ENZYME; SEBELIPASE ALFA; ENZYME;

ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; AUTOSOMAL RECESSIVE DISORDER; BLOOD ANALYSIS; CARDIOLOGIST; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSLIPIDEMIA; ENDOCRINOLOGIST; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FATTY LIVER; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; INFANCY; INHERITANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYSOSOMAL ACID LIPASE DEFICIENCY; MEDICAL SPECIALIST; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING; SPLEEN; SURVIVAL; CHILD; COMPLICATION; DYSLIPIDEMIAS; FEMALE; INFANT; LIVER DISEASES; MALE; NEWBORN; PRESCHOOL CHILD; WOLMAN DISEASE;

ALGORITHMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DYSLIPIDEMIAS; ENZYMES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; PROGNOSIS; WOLMAN DISEASE;

EID: 84901851121     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.003     Document Type: Review

References (90)

1. Bernstein D.L., Hulkova H., Bialer M.G., Desnick R.J. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. JHepatol 2013, 58:1230-1243.
2. Elleder M., Chlumska A., Hyanek J., Poupetova H., Ledvinova J., Maas S., et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. JHepatol 2000, 32:528-534.
3. Elleder M., Chlumska A., Ledvinova J., Poupetova H. Testis- a novel storage site in human cholesteryl ester storage disease. Autopsy report of an adult case with a long-standing subclinical course complicated by accelerated atherosclerosis and liver carcinoma. Virchows Arch 2000, 436:82-87.
4. Hulkova H., Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology 2012, 60:1107-1113.
5. Gasche C., Aslanidis C., Kain R., Exner M., Helbich T., Dejaco C., et al. Anovel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. JHepatol 1997, 27:744-750.
6. Chatrath H., Keilin S., Attar B.M. Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. Dig Dis Sci 2009, 54:168-173.
7. Abramov A., Schorr S., Wolman M. Generalized xanthomatosis with calcified adrenals. AMA J Dis Child 1956, 91:282-286.
8. Fredrickson D.S. Newly recognized disorders of cholesterol metabolism. Ann Intern Med 1963, 58:718.
9. Burke J.A., Schubert W.K. Deficient activity of hepatic acid lipase in cholesterol ester storage disease. Science 1972, 176:309-310.
10. Aslanidis C., Ries S., Fehringer P., Buchler C., Klima H., Schmitz G. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics 1996, 33:85-93.
11. Pagani F., Pariyarath R., Garcia R., Stuani C., Burlina A.B., Ruotolo G., et al. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. JLipid Res 1998, 39:1382-1388.
12. Patrick A.D., Lake B.D. Deficiency of an acid lipase in Wolman's disease. Nature 1969, 222:1067-1068.
13. Stein J., Garty B.Z., Dror Y., Fenig E., Zeigler M., Yaniv I. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr 2007, 166:663-666.
14. Boldrini R., Devito R., Biselli R., Filocamo M., Bosman C. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract 2004, 200:231-240.
15. Grabowski G.A., Charnas L., Du H. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum. Scriver's online metabolic and molecular bases of inherited disease January 2006, McGraw Hill, [accessed 28.10.13]. http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part16/ch142, D. Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.).
16. Jones S.A., Bernstein D.L., Bialer M.G., Dhawan A., Hendriksz J.C., Whitley C.B., et al. Severe and rapid disease course in the natural history of infants with lysosomal acid lipase deficiency. Mol Genet Metab 2014, 111:S57-S58.
17. Fouchier S.W., Defesche J.C. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipidol 2013, 24:332-338.
18. Zhang B., Porto A.F. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. JPediatr Gastroenterol Nutr 2013, 56:682-685.
19. Reynolds T. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. JClin Pathol 2013, 66:918-923.
20. Saito S., Ohno K., Suzuki T., Sakuraba H. Structural bases of Wolman disease and cholesteryl ester storage disease. Mol Genet Metab 2012, 105:244-248.
21. Muntoni S., Wiebusch H., Jansen-Rust M., Rust S., Seedorf U., Schulte H., et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007, 27:1866-1868.
22. Lohse P., Maas S., Elleder M., Kirk J.M., Besley G.T., Seidel D. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. JLipid Res 2000, 41:23-31.
23. Scott S.A., Liu B., Nazarenko I., Martis S., Kozlitina J., Yang Y., et al. Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups. Hepatology 2013, 58:958-965.
24. Stitziel N.O., Fouchier S.W., Sjouke B., Peloso G.M., Moscoso A.M., Auer P.L., et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013, 33:2909-2914.
25. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAm Med Assoc 1999, 281:249-254.
26. Valles-Ayoub Y., Esfandiarifard S., No D., Sinai P., Khokher Z., Kohan M., et al. Wolman disease (LIPA p.G87V) genotype frequency in people of Iranian-Jewish ancestry. Genet Test Mol Biomarkers 2011, 15:395-398.
27. Muntoni S., Wiebusch H., Jansen-Rust M., Rust S., Schulte H., Berger K., et al. Heterozygosity for lysosomal acid lipase E8SJM mutation and serum lipid concentrations. Nutr Metab Cardiovasc Dis 2013, 23:732-736.
28. Goldstein J.L., Dana S.E., Faust J.R., Beaudet A.L., Brown M.S. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. JBiol Chem 1975, 250:8487-8495.
29. Jeon T.I., Osborne T.F. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 2012, 23:65-72.
30. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. JClin Invest 2002, 109:1125-1131.
31. Cummings M.H., Watts G.F. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem 1995, 41:111-114.
32. Ginsberg H.N., Le N.A., Short M.P., Ramakrishnan R., Desnick R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. JClin Invest 1987, 80:1692-1697.
33. Quinn A.G., Burton B., Deegan P., Di Rocco M., Enns G.M., Guardamagna O., et al. Sustained elevations in LDL cholesterol and serum transaminases from early childhood are common in lysosomal acid lipase deficiency. Mol Genet Metab 2014, 111:S89.
34. Garver W.S., Jelinek D., Meaney F.J., Flynn J., Pettit K.M., Shepherd G., et al. The National Niemann-Pick type C1 disease database: correlation of lipid profiles, mutations, and biochemical phenotypes. JLipid Res 2010, 51:406-415.
35. Ramirez C.M., Liu B., Aqul A., Taylor A.M., Repa J.J., Turley S.D., et al. Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations. JLipid Res 2011, 52:688-698.
36. Levy R., Ostlund R.E., Schonfeld G., Wong P., Semenkovich C.F. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. JLipid Res 1992, 33:1005-1015.
37. Oram J.F., Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343-1372.
38. Boadu E., Bilbey N.J., Francis G.A. Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. Curr Opin Lipidol 2008, 19:270-276.
39. Bowden K.L., Bilbey N.J., Bilawchuk L.M., Boadu E., Sidhu R., Ory D.S., et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. JBiol Chem 2011, 286:30624-30635.
40. Beaudet A.L., Ferry G.D., Nichols B.L., Rosenberg H.S. Cholesterol ester storage disease: clinical, biochemical, and pathological studies. JPediatr 1977, 90:910-914.
41. Eto Y., Kitagawa T. Wolman's disease with hypolipoproteinemia and acanthocytosis: clinical and biochemical observations. JPediatr 1970, 77:862-867.
42. vom Dahl S., Harzer K., Rolfs A., Albrecht B., Niederau C., Vogt C., et al. Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. JHepatol 1999, 31:741-746.
43. Drebber U., Andersen M., Kasper H.U., Lohse P., Stolte M., Dienes H.P. Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: a case report. World J Gastroenterol 2005, 11:2364-2366.
44. Haller W., Sharif K., Millar A.J., Brown R.M., McKiernan P.J. Gallbladder dysfunction in cholesterol ester storage disease. JPediatr Gastroenterol Nutr 2010, 50:555-558.
45. Schaub J., Janka G.E., Christomanou H., Sandhoff K., Permanetter W., Hubner G., et al. Wolman's disease: clinical, biochemical and ultrastructural studies in an unusual case without striking adrenal calcification. Eur J Pediatr 1980, 135:45-53.
46. Wallis K., Gross M., Kohn R., Zaidman J. Acase of Wolman's disease. Helv Paediatr Acta 1971, 26:98-111.
47. Kyriakides E.C., Filippone N., Paul B., Grattan W., Balint J.A. Lipid studies in Wolman's disease. Pediatrics 1970, 46:431-436.
48. Marshall W.C., Ockenden B.G., Fosbrooke A.S., Cumings J.N. Wolman's disease. A rare lipidosis with adrenal calcification. Arch Dis Child 1969, 44:331-341.
49. Kostner G.M., Hadorn B., Roscher A., Zechner R. Plasma lipids and lipoproteins ofa patient with cholesteryl ester storage disease. JInherit Metab Dis 1985, 8:9-12.
50. Decarlis S., Agostoni C., Ferrante F., Scarlino S., Riva E., Giovannini M. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. JInherit Metab Dis 2009, 32(Suppl.1):S11-S13.
51. Gaddi A., Cicero A.F., Odoo F.O., Poli A.A., Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag 2007, 3:877-886.
52. Reiner Ž, Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
53. Cortner J.A., Coates P.M., Gallagher P.R. Prevalence and expression of familial combined hyperlipidemia in childhood. JPediatr 1990, 116:514-519.
54. Guardamagna O., Restagno G., Rolfo E., Pederiva C., Martini S., Abello F., et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. JPediatr 2009, 155:199-204.
55. van der Graaf A., Avis H.J., Kusters D.M., Vissers M.N., Hutten B.A., Defesche J.C., et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment ina large cohort of hypercholesterolemic children. Circulation 2011, 123:1167-1173.
56. Guardamagna O., Abello F., Anfossi G., Pirro M. Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. JPediatr 2011, 159:314-319.
57. Pisciotta L., Fresa R., Bellocchio A., Pino E., Guido V., Cantafora A., et al. Cholesteryl Ester Storage Disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab 2009, 97:143-148.
58. The Coronary Artery Disease (C4D) Genetics Consortium Agenome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011, 43:339-344.
59. The IBC 50K CAD Consortium Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011, 7:e1002260.
60. Wild P.S., Zeller T., Schillert A., Szymczak S., Sinning C.R., Deiseroth A., et al. Agenome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet 2011, 4:403-412.
61. Wolman M., Sterk V.V., Gatt S., Frenkel M. Primary familial xanthomatosis with involvement and calcification of the adrenals. Report of two more cases in siblings of a previously described infant. Pediatrics 1961, 28:742-757.
62. Freudenberg F., Bufler P., Ensenauer R., Lohse P., Koletzko S. Cholesteryl ester storage disease: an easily missed diagnosis in oligosymptomatic children. ZGastroenterol 2013, 51:1184-1187.
63. Miltiadous G., Cariolou M.A., Elisaf M. HDL cholesterol levels in patients with molecularly defined familial hypercholesterolemia. Ann Clin Lab Sci 2002, 32:50-54.
64. Iverson S.A., Cairns S.R., Ward C.P., Fensom A.H. Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin. Ann Clin Biochem 1997, 34:433-436.
65. Guardamagna O., Cagliero P., Abello F. Management of inherited atherogenic dyslipidemias in children. Ther Apher Dial 2013, 17:150-161.
66. Hamilton J., Jones I., Srivastava R., Galloway P. Anew method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 2012, 413:1207-1210.
67. Mukherjee M. Human digestive and metabolic lipases- a brief review. JMol Catal B Enzym 2003, 22:369-376.
68. Rosenbaum A.I., Cosner C.C., Mariani C.J., Maxfield F.R., Wiest O., Helquist P. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. JMed Chem 2010, 53:5281-5289.
69. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
70. Vajro P., Lenta S., Socha P., Dhawan A., McKiernan P., Baumann U., et al. D56iagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. JPediatr Gastroenterol Nutr 2012, 54:700-713.
71. Thelwall P.E., Smith F.E., Leavitt M.C., Canty D., Hu W., Hollingsworth K.G., et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. JHepatol 2013, 59:543-549.
72. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
73. Tarantino M.D., McNamara D.J., Granstrom P., Ellefson R.D., Unger E.C., Udall J.N. Lovastatin therapy for cholesterol ester storage disease in two sisters. JPediatr 1991, 118:131-135.
74. Tadiboyina V.T., Liu D.M., Miskie B.A., Wang J., Hegele R.A. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis 2005, 4:26.
75. Yokoyama S., McCoy E. Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin. JInherit Metab Dis 1992, 15:291-292.
76. McCoy E., Yokoyama S. Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. Ann N Y Acad Sci 1991, 623:453-454.
77. Leone L., Ippoliti P.F., Antonicelli R. Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. JPediatr 1991, 119:1008-1009.
78. Abello F., Guardamagna O., Baracco V., Bonardi R. The treatment of colesteryl storage disease (CESD) by ezetimibe monotherapy. Atheroscler Suppl 2010, 11:28.
79. Xu M., Liu K., Swaroop M., Porter F.D., Sidhu R., Firnkes S., et al. δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. JBiol Chem 2012, 287:39349-39360.
80. Tolar J., Petryk A., Khan K., Bjoraker K.J., Jessurun J., Dolan M., et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant 2009, 43:21-27.
81. Gramatges M.M., Dvorak C.C., Regula D.P., Enns G.M., Weinberg K., Agarwal R. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant 2009, 44:449-450.
82. Yanir A., Allatif M.A., Weintraub M., Stepensky P. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Mol Genet Metab 2013, 109:224-226.
83. Ambler G.K., Hoare M., Brais R., Shaw A., Butler A., Flynn P., et al. Orthotopic liver transplantation in an adult with cholesterol ester storage disease. JIMD Rep 2013, 8:41-46.
84. Ferry G.D., Whisennand H.H., Finegold M.J., Alpert E., Glombicki A. Liver transplantation for cholesteryl ester storage disease. JPediatr Gastroenterol Nutr 1991, 12:376-378.
85. Grabowski G.A. Therapy for lysosomal acid lipase deficiency: replacing a missing link. Hepatology 2013, 58:850-852.
86. Balwani M., Breen C., Enns G.M., Deegan P.B., Honzik T., Jones S., et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013, 58:950-957.
87. Whitley CB. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting 2013 [Oral Presentation, 11 October 2013].
88. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007, 194:1-45.
89. Sloan H.R., Fredrickson D.S. Rare familial diseases with neutral lipid storage. The metabolic basis of inherited disease 1972, 808. McGraw Hill Inc, New York. J.B. Stanbury, J.B. Wyngaarden, D.S. Fredrickson (Eds.).
90. Yatsu F.M., Hagemenas F.C., Manaugh L.C., Galambos T. Cholesteryl ester hydrolase activity in human symptomatic atherosclerosis. Lipids 1980, 15:1019-1022.